Clinical Proof-of-concept Study on Immune Surveillance and Alertness

Natural Immune Systems

Status: Enrolling

Conditions: Immune Surveillance

Treatments: Dietary Supplement: Whole Algae

Study type: Interventional

Funder types: Other

Identifiers

NCT05431751

153-012

Details and patient eligibility

About

Clinical proof-of-concept study comparing the acute. effects of an algae-based dietary supplement on immune surveillance and alertness. This study involves twenty-four participants composed of healthy adults, who will be taking either a placebo or supplement at different times. Testing for immune status, cytokine levels, and immune responsiveness will be conducted to determine the acute impact of the supplement on immune function compared to a placebo.

Long term effects and lingering effects will be tested using the same parameters, following a consumption period of one week, as well as a washout period of one week.

Full description

Clinical-proof-of-concept study comparing the acute immune effects as well as the lasting and lingering effects of a dietary supplement, and a placebo. The dietary supplement is composed of whole Euglena gracilis algae, produced using a proprietary fermentation technique.

24 subjects will participate in a placebo-controlled, double-blinded, cross-over study design, wherein they will be taking placebo, or dietary supplement each separated by a 1-week washout period to evaluate rapid effects. Following which the subjects will also be taking placebo or dietary supplement continuously for 1 week each, to evaluate the long term and lingering effects.

For acute evaluation, blood samples are taken 1 hour after participants arrive, the dose is then administered. Samples are take 1 hour and 2 hours following administration. For long-term and lingering evaluation, blood samples are taken 1 hour after participants arrive. At all blood sample collections, a spit sample will also be taken for salivary IgA testing.

A series of immune panels will be used to determine the acute impacts on immune surveillance, immune cell activation status, immune cell priming, and cytokine profiles. Ex vivo immune challenges and salivary IgA testing will be used to determine the direct impacts on immune cells.

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults
• Veins easy to see in both arms
• Willing to comply with a 24-hours wash-out period for vitamins and nutritional supplements
• Willing to comply with study procedures, including maintaining a consistent diet and lifestyle routine throughout the study. Consistent habit of bland breakfasts on days of clinic visits, abstaining from exercising, tobacco use, and nutritional supplements on the morning of a study visit, abstaining from use of coffee, tea, and soft-drinks for at least one hour prior to a clinic visit
• Willing to abstain from music, candy, gum, computer/cellphone use during clinic visits

Exclusion criteria

• Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery not a problem, including previous removal of appendix and gall bladder)
• Taking anti-inflammatory medications on a daily basis (81 mg aspirin is acceptable)
• Vaccination during past 2 weeks
• Currently experiencing intense stressful events/ life changes
• Currently in intensive athletic training (such as marathon runners)
• Currently taking antipsychotic medications such as clozapine, Risperdal, Abilify, Zyprexa or Seroquel
• An unusual sleep routine (examples: working graveyard shift, irregular routine with frequent late nights)
• Unwilling to maintain a constant intake of supplements over the duration of the study
• Anxiety about having blood drawn
• People of childbearing potential: Pregnant, nursing, or trying to become pregnant
• Known food allergies or sensitivities related to the test product or placebo
• Prescription medication will be evaluated on a case-by-case basis

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Crossover Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

Experimental Group A

Experimental group

Description:

Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where they will consume the active intervention. Following the second clinic day, the participant will consume active intervention for 7 days. The participant will then undergo a washout period of 7 days.

Treatment:

Dietary Supplement: Whole Algae